Get the Stockscreener App
60.68
0.06%
0.16
Rhythm Pharmaceuticals Inc stock is traded at $60.68, with a volume of 145.40K.
It is up +0.06% in the last 24 hours and up +24.21% over the past month.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
See More
Previous Close:
$60.84
Open:
$60.49
24h Volume:
145.40K
Relative Volume:
0.33
Market Cap:
$3.74B
Revenue:
$101.78M
Net Income/Loss:
$-259.43M
P/E Ratio:
-18.50
EPS:
-3.28
Net Cash Flow:
$-163.06M
1W Performance:
-1.73%
1M Performance:
+24.21%
6M Performance:
+60.84%
1Y Performance:
+80.16%
1-Day Range:
$60.49
$61.61
1-Week Range:
$60.36
$63.44
52-Week Range:
$32.64
$68.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Compare RYTM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
60.62 | 3.74B | 101.78M | -259.43M | -163.06M | -4.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.81 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.12 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.93 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.34 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.73 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-24 | Initiated | Guggenheim | Buy |
| Sep-18-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | JMP Securities | Mkt Outperform |
| May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-22 | Reiterated | Needham | Buy |
| Mar-02-22 | Resumed | Stifel | Buy |
| Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-14-21 | Resumed | Goldman | Neutral |
| Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-08-20 | Initiated | Goldman | Sell |
| Jul-12-19 | Upgrade | Stifel | Hold → Buy |
| Jul-08-19 | Initiated | Canaccord Genuity | Buy |
| Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
| Sep-07-18 | Resumed | Morgan Stanley | Overweight |
| Jun-25-18 | Reiterated | Needham | Buy |
| Jun-15-18 | Reiterated | Needham | Buy |
| Oct-30-17 | Initiated | BofA/Merrill | Buy |
| Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
12,386 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Intech Investment Management LLC - MarketBeat
Alkeon Capital Management LLC Acquires 167,700 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Victory Capital Management Inc. Has $953,000 Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Purchases 143,800 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Algert Global LLC - MarketBeat
Penserra Capital Management LLC Makes New $1.31 Million Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Gastroparesis Drugs Market to Grow by USD 1.42 Billion (2024-2028), Diabetes Burden Boosts Growth, AI Impact on Market TrendsTechnavio - The Malaysian Reserve
Loomis Sayles & Co. L P Invests $33.35 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Where are the Opportunities in (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals retains stock target, buy rating on new data By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals' (RYTM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts - Inkl
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Principal Financial Group Inc. Increases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals Provides Information to the Shareholders - Marketscreener.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Primecap Management Co. CA - MarketBeat
Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide - GlobeNewswire
Rhythm Pharma: New Drug Shows 9.6% Weight Loss in Pediatric Obesity Treatment Study | RYTM Stock News - StockTitan
Perceptive Advisors LLC's Strategic Acquisition in Rhythm Pharma - GuruFocus.com
(RYTM) Proactive Strategies - Stock Traders Daily
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock By Investing.com - Investing.com Nigeria
Rhythm pharmaceuticals CTO Joseph Shulman sells $882,340 in stock - Investing.com
Rhythm Pharmaceuticals EVP sells $4.43m in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals EVP sells $4.43m in stock - Investing.com
Rhythm Pharmaceuticals Announces Publication of Results - GlobeNewswire
Rhythm Pharma's Obesity Drug Shows 83% Success in Phase 3 Trial, FDA Priority Review Set | RYTM Stock News - StockTitan
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewswire
Rhythm Pharmaceuticals Awards 15,750 RSUs to New Employees in Talent Acquisition Push | RYTM Stock News - StockTitan
PRIMECAP Management Adjusts Stake in Rhythm Pharmaceuticals - GuruFocus.com
Goldman Sachs Group Inc Reduces Stake in Rhythm Pharmaceuticals Inc - GuruFocus.com
High Growth Tech Stocks Featuring Three Prominent US Companies - Simply Wall St
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 52-Week HighWhat's Next? - MarketBeat
HC Wainwright Issues Pessimistic Outlook for RYTM Earnings - MarketBeat
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock By Investing.com - Investing.com Australia
Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Insider Sells 4,688 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals' HR chief Pamela Cramer sells $585,940 in stock - Investing.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $69.00 - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q3 2024 Earnings Call Transcript - Insider Monkey
Rhythm Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance UK
8,594 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Acquired by Creative Planning - MarketBeat
Rhythm Pharmaceuticals Inc (RYTM) Q3 2024 Earnings Call Highligh - GuruFocus.com
Earnings call: Rhythm Pharmaceuticals has reported a successful third quarter in 2024 - Investing.com India
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences - GlobeNewswire
Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $64.00 at Needham & Company LLC - MarketBeat
Rhythm Pharmaceuticals CEO to Present at Major Healthcare Investor Conferences | RYTM Stock News - StockTitan
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Gastroparesis Drugs Market to Grow by USD 1.42 Billion from 2024-2028, Driven by Rising Diabetes Rates and AI-Driven Market Trend InsightsTechnavio - The Malaysian Reserve
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewswire
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 1-Year HighTime to Buy? - MarketBeat
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):